Ensysce Biosciences Begins Phase 3 PF614-MPAR-102 Trial With Overdose Protection Tech
ENSC•Ensysce Biosciences has enrolled the first patient in the Phase 3 PF614-MPAR-102 study evaluating its MPAR® technology engineered to automatically restrict opioid release under supratherapeutic dosing. Clinical data to date show consistent therapeutic plasma levels at prescribed doses and significant blunting of exposure at overdose levels.
1. Phase 3 Trial Launch
Ensysce enrolled its first patient in the final stage of the PF614-MPAR-102 clinical study, marking the transition to Phase 3 evaluation of its novel MPAR® platform. The study, supported by the National Institute on Drug Abuse, will assess protective performance across a broader range of dosing scenarios to validate overdose resistance in oral opioid therapy.
2. MPAR® Overdose Protection Mechanism
The MPAR® platform incorporates a proprietary chemical‐control mechanism that delivers therapeutic opioid exposure at prescribed doses while activating a built-in safety switch to restrict additional release when excessive amounts are ingested. Prior trial data demonstrated consistent plasma drug levels at normal dosing and significant blunting of supratherapeutic exposure.
3. Development and Pipeline Expansion
Beyond the PF614 opioid candidate, Ensysce plans to extend its MPAR® technology to amphetamines and methadone for ADHD and opioid use disorder treatments. The Company aims to establish a new standard for safety by embedding overdose protection directly into multiple classes of central nervous system therapeutics.
